German biotech's uveal melanoma cell therapy shrinks tumors in all 16 Phase 1 patients
Start here
At a major European oncology conference, a German biotech presented Phase 1 data for its cell therapy targeting uveal melanoma, a rare and typically treatment-resistant eye cancer. Tumors shrank in all 16 patients treated in the trial. The company, which has positioned itself in cancer, still needs to win its first regulatory approval for a medicine. Oncologist Sapna Patel noted the target could potentially extend to immunotherapy-resistant solid tumors such as pancreatic and ovarian cancer. What remains open is whether the early tumor responses hold up in larger trials and whether the therapy can progress to approval.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- STATPickSTAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
At a major European oncology conference, a German biotech presented Phase 1 data for its uveal melanoma cell therapy: tumors shrank in all 16 patients. Oncologist Sapna Patel noted the target could extend to immunotherapy-resistant solid tumors such as pancreatic and ovarian cancer.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 17:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.